IOVA - Iovance Biotherapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Carlos,
United States
Type: Equity
IOVA price evolution
IOVA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $235.11 | $140.62 | $181.32 | |
| Short term investments | $183.86 | $222.01 | $164.98 | |
| Net receivables | $55.77 | $31.6 | $0.23 | $0.15 |
| Inventory | $38.58 | $27.85 | $17.62 | $10.37 |
| Total current assets | $498.58 | $482.26 | $385.53 | $307.85 |
| Long term investments | ||||
| Property, plant & equipment | $179.26 | $180.08 | $183.31 | $176.54 |
| Goodwill & intangible assets | $295.3 | $294.3 | $229.26 | |
| Total noncurrent assets | $482.06 | $484.3 | $472.5 | |
| Total investments | $183.86 | $222.01 | $164.98 | |
| Total assets | $991.12 | $964.32 | $869.83 | $780.35 |
| Current liabilities | ||||
| Accounts payable | $31.69 | $20.42 | $25.7 | $33.12 |
| Deferred revenue | ||||
| Short long term debt | $11.44 | $11.08 | $7.78 | |
| Total current liabilities | $118.06 | $93.64 | $83.21 | $110.31 |
| Long term debt | $1 | $70.25 | $73.29 | $68.08 |
| Total noncurrent liabilities | $102.14 | $106.59 | $85.43 | |
| Total debt | $81.68 | $84.37 | $75.86 | |
| Total liabilities | $217.66 | $195.78 | $189.81 | $195.74 |
| Shareholders' equity | ||||
| Retained earnings | -$2305.99 | -$2222.45 | -$2125.35 | -$2012.38 |
| Other shareholder equity | $16.24 | $0.53 | $0.12 | $2.53 |
| Total shareholder equity | $768.54 | $680.02 | $584.61 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $181.32 | $238.16 | $84.31 | $72.85 |
| Short term investments | $164.98 | $240.11 | $426.18 | $562.11 |
| Net receivables | $0.15 | |||
| Inventory | $10.37 | |||
| Total current assets | $307.85 | $479.12 | $507.96 | $636.1 |
| Long term investments | $91.59 | |||
| Property, plant & equipment | $176.54 | $178.25 | $169.92 | $113.92 |
| Goodwill & intangible assets | $229.26 | |||
| Total noncurrent assets | $472.5 | $184.87 | $269.38 | $132.36 |
| Total investments | $164.98 | $240.11 | $517.77 | $562.11 |
| Total assets | $780.35 | $663.98 | $777.33 | $768.46 |
| Current liabilities | ||||
| Accounts payable | $33.12 | $26.6 | $27.38 | $13.51 |
| Deferred revenue | ||||
| Short long term debt | $7.78 | $12.59 | $5.06 | $6.28 |
| Total current liabilities | $110.31 | $91.48 | $89.2 | $54.87 |
| Long term debt | $68.08 | $1 | $66.47 | $45.38 |
| Total noncurrent liabilities | $85.43 | $72.86 | $66.47 | $57.09 |
| Total debt | $75.86 | $85.45 | $71.53 | $51.66 |
| Total liabilities | $195.74 | $164.34 | $155.67 | $111.96 |
| Shareholders' equity | ||||
| Retained earnings | -$2012.38 | -$1568.34 | -$1172.44 | -$830.19 |
| Other shareholder equity | $2.53 | -$0.9 | -$0.6 | $0.02 |
| Total shareholder equity | $584.61 | $499.64 | $621.66 | $656.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $31.11 | $0.71 | $0.48 | |
| Cost of revenue | $31.37 | $7.26 | $4.37 | |
| Gross Profit | -$0.26 | -$6.55 | -$3.88 | |
| Operating activities | ||||
| Research & development | $62.08 | $79.78 | $87.47 | |
| Selling, general & administrative | $39.57 | $31.39 | $29.9 | |
| Total operating expenses | $101.65 | $111.18 | $117.37 | |
| Operating income | -$101.91 | -$117.72 | -$121.26 | |
| Income from continuing operations | ||||
| EBIT | -$98.56 | -$114.38 | -$118.14 | |
| Income tax expense | -$1.46 | -$1.41 | -$1.76 | |
| Interest expense | ||||
| Net income | ||||
| Net income | -$97.1 | -$112.98 | -$116.38 | |
| Income (for common shares) | -$97.1 | -$112.98 | -$116.38 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.19 | |||
| Cost of revenue | $10.76 | |||
| Gross Profit | -$9.57 | |||
| Operating activities | ||||
| Research & development | $344.08 | $294.78 | $259.04 | $201.73 |
| Selling, general & administrative | $106.92 | $104.1 | $83.66 | $60.21 |
| Total operating expenses | $450.99 | $398.88 | $342.7 | $261.94 |
| Operating income | -$460.56 | -$398.88 | -$342.7 | -$261.94 |
| Income from continuing operations | ||||
| EBIT | -$447.52 | -$395.89 | -$342.25 | -$259.58 |
| Income tax expense | -$3.48 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$444.04 | -$395.89 | -$342.25 | -$259.58 |
| Income (for common shares) | -$444.04 | -$395.89 | -$342.25 | -$259.58 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$97.1 | -$112.98 | -$116.38 | |
| Operating activities | ||||
| Depreciation | $10.86 | $9.91 | $9.71 | |
| Business acquisitions & disposals | -$52.57 | $0.25 | ||
| Stock-based compensation | $30.47 | $17.18 | $14.4 | |
| Total cash flows from operations | -$98.43 | -$122.28 | -$83.97 | |
| Investing activities | ||||
| Capital expenditures | -$0.44 | -$4.17 | -$3.53 | |
| Investments | $40.66 | -$54.76 | -$69.57 | |
| Total cash flows from investing | -$120.09 | $40.22 | -$111.51 | -$72.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $153.82 | $198.28 | $1.15 | |
| Net borrowings | ||||
| Total cash flows from financing | $388.36 | $152.82 | $193.58 | $0.96 |
| Effect of exchange rate | $0.64 | -$0.13 | -$0.49 | $3.02 |
| Change in cash and equivalents | -$10.78 | $94.49 | -$40.7 | -$152.83 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$444.04 | -$395.89 | -$342.25 | -$259.58 |
| Operating activities | ||||
| Depreciation | $33.13 | $21.14 | $13.98 | $8.71 |
| Business acquisitions & disposals | -$212.63 | |||
| Stock-based compensation | $62.63 | $84.02 | $69.77 | $40.89 |
| Total cash flows from operations | -$361.82 | -$292.76 | -$227.94 | -$205.13 |
| Investing activities | ||||
| Capital expenditures | -$22.29 | -$20.43 | -$37.57 | -$46.79 |
| Investments | $79.68 | $276.88 | $37.71 | -$271.06 |
| Total cash flows from investing | -$155.24 | $256.45 | $0.13 | -$317.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $465.75 | $192.8 | $238.27 | $576.71 |
| Net borrowings | $1 | |||
| Total cash flows from financing | $462.96 | $190.15 | $239.27 | $576.42 |
| Effect of exchange rate | -$2.74 | |||
| Change in cash and equivalents | -$56.84 | $153.85 | $11.46 | $53.44 |
News
Fundamentals
| Market cap | $2.25B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 304.62M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.22 |
| Quick ratio | 3.90 |